Genomic and Epigenomic Alterations in Cancer

American Journal of Pathology

Volumn 186, Issue 7, 2016, Pages 1724-1735

  Chakravarthi, Balabhadrapatruni V S K ^a   Nepal, Saroj ^a   Varambally, Sooryanarayana ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNTRANSLATED RNA;

CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; DNA MODIFICATION; EPIGENETICS; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUSION; GENE MUTATION; GENETIC VARIATION; GENOMICS; HISTONE MODIFICATION; HUMAN; IMMUNE SYSTEM; METABOLOMICS; METASTASIS; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; ANIMAL; GENETICS; NEOPLASM; TRENDS;

ANIMALS; EPIGENOMICS; HUMANS; NEOPLASMS;

EID: 84997525157     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2016.02.023     Document Type: Review

References (122)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
2. 2 Stratton, M.R., Campbell, P.J., Futreal, P.A., The cancer genome. Nature 458 (2009), 719–724.
3. 3 Talbot, S.J., Crawford, D.H., Viruses and tumours: an update. Eur J Cancer 40 (2004), 1998–2005.
4. 4 Olivier, M., Hussain, S.P., Caron de Fromentel, C., Hainaut, P., Harris, C.C., TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ, 2004, 247–270.
5. 5 Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007), 153–158.
6. 6 Miller, D.G., On the nature of susceptibility to cancer: the presidential address. Cancer 46 (1980), 1307–1318.
7. 7 Dawson, M.A., Kouzarides, T., Cancer epigenetics: from mechanism to therapy. Cell 150 (2012), 12–27.
8. 8 Sharma, S., Kelly, T.K., Jones, P.A., Epigenetics in cancer. Carcinogenesis 31 (2010), 27–36.
9. 9 Fullgrabe, J., Kavanagh, E., Joseph, B., Histone onco-modifications. Oncogene 30 (2011), 3391–3403.
10. 10 Bannister, A.J., Kouzarides, T., Regulation of chromatin by histone modifications. Cell Res 21 (2011), 381–395.
11. 11 Rossetto, D., Avvakumov, N., Cote, J., Histone phosphorylation: a chromatin modification involved in diverse nuclear events. Epigenetics 7 (2012), 1098–1108.
12. 12 Esteller, M., Epigenetics in cancer. N Engl J Med 358 (2008), 1148–1159.
13. 13 Jones, P.A., Baylin, S.B., The epigenomics of cancer. Cell 128 (2007), 683–692.
14. 14 Gonzalgo, M.L., Nakayama, M., Lee, S.M., De Marzo, A.M., Nelson, W.G., Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 63 (2004), 414–418.
15. 15 Jenuwein, T., Allis, C.D., Translating the histone code. Science 293 (2001), 1074–1080.
16. 16 Baylin, S.B., Ohm, J.E., Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 6 (2006), 107–116.
17. 17 van Haaften, G., Dalgliesh, G.L., Davies, H., Chen, L., Bignell, G., Greenman, C., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41 (2009), 521–523.
18. 18 Morin, R.D., Mendez-Lago, M., Mungall, A.J., Goya, R., Mungall, K.L., Corbett, R.D., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476 (2011), 298–303.
19. 19 Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42 (2010), 181–185.
20. 20 Xi, R., Hadjipanayis, A.G., Luquette, L.J., Kim, T.M., Lee, E., Zhang, J., Johnson, M.D., Muzny, D.M., Wheeler, D.A., Gibbs, R.A., Kucherlapati, R., Park, P.J., Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proc Natl Acad Sci U S A 108 (2011), E1128–E1136.
21. 21 Mertens, F., Johansson, B., Fioretos, T., Mitelman, F., The emerging complexity of gene fusions in cancer. Nat Rev Cancer 15 (2015), 371–381.
22. 22 Tomlins, S.A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X.W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J.E., Shah, R.B., Pienta, K.J., Rubin, M.A., Chinnaiyan, A.M., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005), 644–648.
23. 23 Kumar-Sinha, C., Tomlins, S.A., Chinnaiyan, A.M., Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8 (2008), 497–511.
24. 24 Edgren, H., Murumagi, A., Kangaspeska, S., Nicorici, D., Hongisto, V., Kleivi, K., Rye, I.H., Nyberg, S., Wolf, M., Borresen-Dale, A.L., Kallioniemi, O., Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol, 12, 2011, R6.
25. 25 Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., Kumar-Sinha, C., Dhanasekaran, S.M., Chen, Y.B., Esgueva, R., Banerjee, S., LaFargue, C.J., Siddiqui, J., Demichelis, F., Moeller, P., Bismar, T.A., Kuefer, R., Fullen, D.R., Johnson, T.M., Greenson, J.K., Giordano, T.J., Tan, P., Tomlins, S.A., Varambally, S., Rubin, M.A., Maher, C.A., Chinnaiyan, A.M., Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16 (2010), 793–798.
26. 26 Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., Mano, H., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
27. 27 Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., Lecluse, Y., Plo, I., Dreyfus, F.J., Marzac, C., Casadevall, N., Lacombe, C., Romana, S.P., Dessen, P., Soulier, J., Viguie, F., Fontenay, M., Vainchenker, W., Bernard, O.A., Mutation in TET2 in myeloid cancers. N Engl J Med 360 (2009), 2289–2301.
28. 28 Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z., Wolniak, K., Peeters, J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Lowenberg, B., Licht, J.D., Godley, L.A., Delwel, R., Valk, P.J., Thompson, C.B., Levine, R.L., Melnick, A., Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18 (2010), 553–567.
29. 29 Wilson, A.S., Power, B.E., Molloy, P.L., DNA hypomethylation and human diseases. Biochim Biophys Acta 1775 (2007), 138–162.
30. 30 Lin, J.C., Jeong, S., Liang, G., Takai, D., Fatemi, M., Tsai, Y.C., Egger, G., Gal-Yam, E.N., Jones, P.A., Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 12 (2007), 432–444.
31. 31 Issa, J.P., CpG island methylator phenotype in cancer. Nat Rev Cancer 4 (2004), 988–993.
32. 32 Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Sewalt, R.G., Otte, A.P., Hayes, D.F., Sabel, M.S., Livant, D., Weiss, S.J., Rubin, M.A., Chinnaiyan, A.M., EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100 (2003), 11606–11611.
33. 33 Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., Ghosh, D., Pienta, K.J., Sewalt, R.G., Otte, A.P., Rubin, M.A., Chinnaiyan, A.M., The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002), 624–629.
34. 34 Asangani, I.A., Ateeq, B., Cao, Q., Dodson, L., Pandhi, M., Kunju, L.P., Mehra, R., Lonigro, R.J., Siddiqui, J., Palanisamy, N., Wu, Y.M., Cao, X., Kim, J.H., Zhao, M., Qin, Z.S., Iyer, M.K., Maher, C.A., Kumar-Sinha, C., Varambally, S., Chinnaiyan, A.M., Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 49 (2013), 80–93.
35. 35 Ceol, C.J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D.A., Battisti, V., Fritsch, L., Lin, W.M., Hollmann, T.J., Ferre, F., Bourque, C., Burke, C.J., Turner, L., Uong, A., Johnson, L.A., Beroukhim, R., Mermel, C.H., Loda, M., Ait-Si-Ali, S., Garraway, L.A., Young, R.A., Zon, L.I., The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471 (2011), 513–517.
36. 36 Yamaguchi, H., Hung, M.C., Regulation and role of EZH2 in cancer. Cancer Res Treat 46 (2014), 209–222.
37. 37 Kim, J.H., Sharma, A., Dhar, S.S., Lee, S.H., Gu, B., Chan, C.H., Lin, H.K., Lee, M.G., UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res 74 (2014), 1705–1717.
38. 38 Rodriguez-Paredes, M., Martinez de Paz, A., Simo-Riudalbas, L., Sayols, S., Moutinho, C., Moran, S., Villanueva, A., Vazquez-Cedeira, M., Lazo, P.A., Carneiro, F., Moura, C.S., Vieira, J., Teixeira, M.R., Esteller, M., Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene 33 (2014), 2807–2813.
39. 39 Sun, Y., Wei, M., Ren, S.C., Chen, R., Xu, W.D., Wang, F.B., Lu, J., Shen, J., Yu, Y.W., Hou, J.G., Xu, C.L., Huang, J.T., Sun, Y.H., Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion. Asian J Androl 16 (2014), 319–324.
40. 40 Guan, X., Zhong, X., Men, W., Gong, S., Zhang, L., Han, Y., Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer. Mol Clin Oncol 2 (2014), 76–80.
41. 41 Cho, H.S., Kelly, J.D., Hayami, S., Toyokawa, G., Takawa, M., Yoshimatsu, M., Tsunoda, T., Field, H.I., Neal, D.E., Ponder, B.A., Nakamura, Y., Hamamoto, R., Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia 13 (2011), 676–684.
42. 42 Hoffmann, I., Roatsch, M., Schmitt, M.L., Carlino, L., Pippel, M., Sippl, W., Jung, M., The role of histone demethylases in cancer therapy. Mol Oncol 6 (2012), 683–703.
43. 43 Ozdag, H., Batley, S.J., Forsti, A., Iyer, N.G., Daigo, Y., Boutell, J., Arends, M.J., Ponder, B.A., Kouzarides, T., Caldas, C., Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. Br J Cancer 87 (2002), 1162–1165.
44. 44 Santos-Rosa, H., Caldas, C., Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41 (2005), 2381–2402.
45. 45 Choi, J.H., Kwon, H.J., Yoon, B.I., Kim, J.H., Han, S.U., Joo, H.J., Kim, D.Y., Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92 (2001), 1300–1304.
46. 46 Halkidou, K., Gaughan, L., Cook, S., Leung, H.Y., Neal, D.E., Robson, C.N., Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59 (2004), 177–189.
47. 47 Fu, J., Bian, M., Jiang, Q., Zhang, C., Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5 (2007), 1–10.
48. 48 Grabsch, H., Takeno, S., Parsons, W.J., Pomjanski, N., Boecking, A., Gabbert, H.E., Mueller, W., Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer: association with tumour cell proliferation. J Pathol 200 (2003), 16–22.
49. 49 Wang, H., Wang, L., Erdjument-Bromage, H., Vidal, M., Tempst, P., Jones, R.S., Zhang, Y., Role of histone H2A ubiquitination in Polycomb silencing. Nature 431 (2004), 873–878.
50. 50 Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R.S., Zhang, Y., Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298 (2002), 1039–1043.
51. 51 Kim, K.H., Roberts, C.W., Targeting EZH2 in cancer. Nat Med 22 (2016), 128–134.
52. 52 Hohmann, A.F., Vakoc, C.R., A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet 30 (2014), 356–363.
53. 53 Wu, R.C., Wang, T.L., Shih Ie, M., The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther 15 (2014), 655–664.
54. 54 Masliah-Planchon, J., Bieche, I., Guinebretiere, J.M., Bourdeaut, F., Delattre, O., SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol 10 (2015), 145–171.
55. 55 Sanger, F., Nicklen, S., Coulson, A.R., DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74 (1977), 5463–5467.
56. 56 Ronaghi, M., Uhlen, M., Nyren, P., A sequencing method based on real-time pyrophosphate. Science 281 (1998), 363–365.
57. 57 Metzker, M.L., Sequencing technologies: the next generation. Nat Rev Genet 11 (2010), 31–46.
58. 58 Mody, R.J., Wu, Y.M., Lonigro, R.J., Cao, X., Roychowdhury, S., Vats, P., Frank, K.M., Prensner, J.R., Asangani, I., Palanisamy, N., Dillman, J.R., Rabah, R.M., Kunju, L.P., Everett, J., Raymond, V.M., Ning, Y., Su, F., Wang, R., Stoffel, E.M., Innis, J.W., Roberts, J.S., Robertson, P.L., Yanik, G., Chamdin, A., Connelly, J.A., Choi, S., Harris, A.C., Kitko, C., Rao, R.J., Levine, J.E., Castle, V.P., Hutchinson, R.J., Talpaz, M., Robinson, D.R., Chinnaiyan, A.M., Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA 314 (2015), 913–925.
59. 59 Meldrum, C., Doyle, M.A., Tothill, R.W., Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 32 (2011), 177–195.
60. 60 Chmielecki, J., Meyerson, M., DNA sequencing of cancer: what have we learned?. Annu Rev Med 65 (2014), 63–79.
61. 61 Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
62. 62 Chiu, R.W., Lo, Y.M., Non-invasive prenatal diagnosis by fetal nucleic acid analysis in maternal plasma: the coming of age. Semin Fetal Neonatal Med 16 (2011), 88–93.
63. 63 Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson, M.D., Niu, B., McLellan, M.D., Uzunangelov, V., Zhang, J., Kandoth, C., Akbani, R., Shen, H., Omberg, L., Chu, A., Margolin, A.A., Van't Veer, L.J., Lopez-Bigas, N., Laird, P.W., Raphael, B.J., Ding, L., Robertson, A.G., Byers, L.A., Mills, G.B., Weinstein, J.N., Van Waes, C., Chen, Z., Collisson, E.A., Cancer Genome Atlas Research Network, Benz, C.C., Perou, C.M., Stuart, J.M., Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158 (2014), 929–944.
64. 64 Melo, S.A., Esteller, M., Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 585 (2011), 2087–2099.
65. 65 Schanen, B.C., Li, X., Transcriptional regulation of mammalian miRNA genes. Genomics 97 (2011), 1–6.
66. 66 Cao, Q., Mani, R.S., Ateeq, B., Dhanasekaran, S.M., Asangani, I.A., Prensner, J.R., Kim, J.H., Brenner, J.C., Jing, X., Cao, X., Wang, R., Li, Y., Dahiya, A., Wang, L., Pandhi, M., Lonigro, R.J., Wu, Y.M., Tomlins, S.A., Palanisamy, N., Qin, Z., Yu, J., Maher, C.A., Varambally, S., Chinnaiyan, A.M., Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 20 (2011), 187–199.
67. 67 Saito, Y., Liang, G., Egger, G., Friedman, J.M., Chuang, J.C., Coetzee, G.A., Jones, P.A., Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9 (2006), 435–443.
68. 68 Varambally, S., Cao, Q., Mani, R.S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., Brenner, J.C., Yu, J., Kim, J.H., Han, B., Tan, P., Kumar-Sinha, C., Lonigro, R.J., Palanisamy, N., Maher, C.A., Chinnaiyan, A.M., Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322 (2008), 1695–1699.
69. 69 Friedman, J.M., Liang, G., Liu, C.C., Wolff, E.M., Tsai, Y.C., Ye, W., Zhou, X., Jones, P.A., The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 69 (2009), 2623–2629.
70. 70 Dorsett, Y., McBride, K.M., Jankovic, M., Gazumyan, A., Thai, T.H., Robbiani, D.F., Di Virgilio, M., Reina San-Martin, B., Heidkamp, G., Schwickert, T.A., Eisenreich, T., Rajewsky, K., Nussenzweig, M.C., MicroRNA-155 suppresses activation-induced cytidine deaminasemediated Myc-Igh translocation. Immunity 28 (2008), 630–638.
71. 71 Qi, L., Bart, J., Tan, L.P., Platteel, I., Sluis, T., Huitema, S., Harms, G., Fu, L., Hollema, H., Berg, A., Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer, 9, 2009, 163.
72. 72 Chan, J.A., Krichevsky, A.M., Kosik, K.S., MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65 (2005), 6029–6033.
73. 73 Folini, M., Gandellini, P., Longoni, N., Profumo, V., Callari, M., Pennati, M., Colecchia, M., Supino, R., Veneroni, S., Salvioni, R., Valdagni, R., Daidone, M.G., Zaffaroni, N., miR-21: an oncomir on strike in prostate cancer. Mol Cancer, 9, 2010, 12.
74. 74 Ma, L., Teruya-Feldstein, J., Weinberg, R.A., Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449 (2007), 682–688.
75. 75 Iyer, M.K., Niknafs, Y.S., Malik, R., Singhal, U., Sahu, A., Hosono, Y., Barrette, T.R., Prensner, J.R., Evans, J.R., Zhao, S., Poliakov, A., Cao, X., Dhanasekaran, S.M., Wu, Y.M., Robinson, D.R., Beer, D.G., Feng, F.Y., Iyer, H.K., Chinnaiyan, A.M., The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 47 (2015), 199–208.
76. 76 Cheetham, S.W., Gruhl, F., Mattick, J.S., Dinger, M.E., Long noncoding RNAs and the genetics of cancer. Br J Cancer 108 (2013), 2419–2425.
77. 77 Prensner, J.R., Iyer, M.K., Balbin, O.A., Dhanasekaran, S.M., Cao, Q., Brenner, J.C., Laxman, B., Asangani, I.A., Grasso, C.S., Kominsky, H.D., Cao, X., Jing, X., Wang, X., Siddiqui, J., Wei, J.T., Robinson, D., Iyer, H.K., Palanisamy, N., Maher, C.A., Chinnaiyan, A.M., Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29 (2011), 742–749.
78. 78 Mehra, R., Udager, A.M., Ahearn, T.U., Cao, X., Feng, F.Y., Loda, M., Petimar, J.S., Kantoff, P., Mucci, L.A., Chinnaiyan, A.M., Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer. Eur Urol, 2015 [Epub ahead of print] doi: 10.1016/j.eururo.2015.12.003.
79. 79 Prensner, J.R., Iyer, M.K., Sahu, A., Asangani, I.A., Cao, Q., Patel, L., Vergara, I.A., Davicioni, E., Erho, N., Ghadessi, M., Jenkins, R.B., Triche, T.J., Malik, R., Bedenis, R., McGregor, N., Ma, T., Chen, W., Han, S., Jing, X., Cao, X., Wang, X., Chandler, B., Yan, W., Siddiqui, J., Kunju, L.P., Dhanasekaran, S.M., Pienta, K.J., Feng, F.Y., Chinnaiyan, A.M., The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 45 (2013), 1392–1398.
80. 80 Liz, J., Esteller, M., lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta 1859 (2016), 169–176.
81. 81 Prensner, J.R., Chen, W., Han, S., Iyer, M.K., Cao, Q., Kothari, V., Evans, J.R., Knudsen, K.E., Paulsen, M.T., Ljungman, M., Lawrence, T.S., Chinnaiyan, A.M., Feng, F.Y., The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia 16 (2014), 900–908.
82. 82 Herceg, Z., Hainaut, P., Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol 1 (2007), 26–41.
83. 83 Otsuka, J., Okuda, T., Sekizawa, A., Amemiya, S., Saito, H., Okai, T., Kushima, M., Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer 14 (2004), 459–464.
84. 84 Jackson, P.E., Kuang, S.Y., Wang, J.B., Strickland, P.T., Munoz, A., Kensler, T.W., Qian, G.S., Groopman, J.D., Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 24 (2003), 1657–1663.
85. 85 Gormally, E., Vineis, P., Matullo, G., Veglia, F., Caboux, E., Le Roux, E., et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res 66 (2006), 6871–6876.
86. 86 Olivier, M., Langerod, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bieche, I., Varley, J., Bignon, Y., Uhrhammer, N., Winqvist, R., Jukkola-Vuorinen, A., Niederacher, D., Kato, S., Ishioka, C., Hainaut, P., Borresen-Dale, A.L., The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12 (2006), 1157–1167.
87. 87 Shigematsu, H., Gazdar, A.F., Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118 (2006), 257–262.
88. 88 Stefansson, O.A., Esteller, M., Epigenetic modifications in breast cancer and their role in personalized medicine. Am J Pathol 183 (2013), 1052–1063.
89. 89 Fraga, M.F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., Iyer, N.G., Pérez-Rosado, A., Calvo, E., Lopez, J.A., Cano, A., Calasanz, M.J., Colomer, D., Piris, M.A., Ahn, N., Imhof, A., Caldas, C., Jenuwein, T., Esteller, M., Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37 (2005), 391–400.
90. 90 Salagierski, M., Schalken, J.A., Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 187 (2012), 795–801.
91. 91 Germenis, A.E., Karanikas, V., Immunoepigenetics: the unseen side of cancer immunoediting. Immunol Cell Biol 85 (2007), 55–59.
92. 92 Kim, R., Emi, M., Tanabe, K., Cancer immunoediting from immune surveillance to immune escape. Immunology 121 (2007), 1–14.
93. 93 Parcesepe, P., Giordano, G., Laudanna, C., Febbraro, A., Pancione, M., Cancer-associated immune resistance and evasion of immune surveillance in colorectal cancer. Gastroenterol Res Pract, 2016, 2016, 6261721.
94. 94 Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
95. 95 Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
96. 96 Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., Kohrt, H.E., Horn, L., Lawrence, D.P., Rost, S., Leabman, M., Xiao, Y., Mokatrin, A., Koeppen, H., Hegde, P.S., Mellman, I., Chen, D.S., Hodi, F.S., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
97. 97 Taube, J.M., Klein, A., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., Chen, L., Pardoll, D.M., Topalian, S.L., Anders, R.A., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20 (2014), 5064–5074.
98. 98 Weinstock, M., McDermott, D., Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 7 (2015), 365–377.
99. 99 Kim, J.W., Eder, J.P., Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology (Williston Park) 28:Suppl 3 (2014), 15–28.
100. 100 Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., Pitot, H.C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T.M., Alaparthy, S., Grosso, J.F., Korman, A.J., Parker, S.M., Agrawal, S., Goldberg, S.M., Pardoll, D.M., Gupta, A., Wigginton, J.M., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
101. 101 Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., Benci, J.L., Xu, B., Dada, H., Odorizzi, P.M., Herati, R.S., Mansfield, K.D., Patsch, D., Amaravadi, R.K., Schuchter, L.M., Ishwaran, H., Mick, R., Pryma, D.A., Xu, X., Feldman, M.D., Gangadhar, T.C., Hahn, S.M., Wherry, E.J., Vonderheide, R.H., Minn, A.J., Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
102. 102 Beltran, A., Parikh, S., Liu, Y., Cuevas, B.D., Johnson, G.L., Futscher, B.W., Blancafort, P., Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 26 (2007), 2791–2798.
103. 103 Gonzalgo, M.L., Nakayama, M., Lee, S.M., De Marzo, A.M., Nelson, W.G., Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 63 (2004), 414–418.
104. 104 Thon, N., Kreth, S., Kreth, F.W., Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets Ther 6 (2013), 1363–1372.
105. 105 Mack, G.S., Epigenetic cancer therapy makes headway. J Natl Cancer Inst 98 (2006), 1443–1444.
106. 106 Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., Frankel, S.R., Chen, C., Ricker, J.L., Arduino, J.M., Duvic, M., Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (2007), 3109–3115.
107. 107 Hunter, P., The second coming of epigenetic drugs: a more strategic and broader research framework could boost the development of new drugs to modify epigenetic factors and gene expression. EMBO Rep 16 (2015), 276–279.
108. 108 Deisseroth, A., Kaminskas, E., Grillo, J., Chen, W., Saber, H., Lu, H.L., Rothmann, M.D., Brar, S., Wang, J., Garnett, C., Bullock, J., Burke, L.B., Rahman, A., Sridhara, R., Farrell, A., Pazdur, R., U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 18 (2012), 3212–3217.
109. 109 Ott, M., Verdin, E., HAT trick: p300, small molecule, inhibitor. Chem Biol 17 (2010), 417–418.
110. 110 Fu, L.L., Tian, M., Li, X., Li, J.J., Huang, J., Ouyang, L., Zhang, Y., Liu, B., Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget 6 (2015), 5501–5516.
111. 111 Deng, Y., Zhang, Y., Sun, S., Wang, Z., Wang, M., Yu, B., Czajkowsky, D.M., Liu, B., Li, Y., Wei, W., Shi, Q., An integrated microfluidic chip system for single-cell secretion profiling of rare circulating tumor cells. Sci Rep, 4, 2014, 7499.
112. 112 Balic, M., Lin, H., Williams, A., Datar, R.H., Cote, R.J., Progress in circulating tumor cell capture and analysis: implications for cancer management. Expert Rev Mol Diagn 12 (2012), 303–312.
113. 113 Zill, O.A., Greene, C., Sebisanovic, D., Siew, L., Leng, J., Vu, M., Hendifar, A.E., Wang, Z., Atreya, C.E., Kelley, R.K., Van Loon, K., Ko, A.H., Tempero, M.A., Bivona, T.G., Munster, P.N., Talasaz, A., Collisson, E., Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov 5 (2015), 1040–1048.
114. 114 Naik, S.H., Schumacher, T.N., Perie, L., Cellular barcoding: a technical appraisal. Exp Hematol 42 (2014), 598–608.
115. 115 Mali, P., Aach, J., Lee, J.H., Levner, D., Nip, L., Church, G.M., Barcoding cells using cell-surface programmable DNA-binding domains. Nat Methods 10 (2013), 403–406.
116. 116 Doudna, J.A., Charpentier, E., Genome editing: the new frontier of genome engineering with CRISPR-Cas9. Science, 346, 2014, 1258096.
117. 117 Harrison, M.M., Jenkins, B.V., O'Connor-Giles, K.M., Wildonger, J., A CRISPR view of development. Genes Dev 28 (2014), 1859–1872.
118. 118 Siolas, D., Hannon, G.J., Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73 (2013), 5315–5319.
119. 119 Aparicio, S., Hidalgo, M., Kung, A.L., Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 15 (2015), 311–316.
120. 120 Hidalgo, M., Amant, F., Biankin, A.V., Budinska, E., Byrne, A.T., Caldas, C., Clarke, R.B., de Jong, S., Jonkers, J., Maelandsmo, G.M., Roman-Roman, S., Seoane, J., Trusolino, L., Villanueva, A., Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4 (2014), 998–1013.
121. 121 Martinez-Garcia, R., Juan, D., Rausell, A., Munoz, M., Banos, N., Menendez, C., Lopez-Casas, P.P., Rico, D., Valencia, A., Hidalgo, M., Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med, 6, 2014, 27.
122. 122 Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I., Engle, D.D., Corbo, V., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160 (2015), 324–338.